Exenatide added to insulin glargine-treated patients with type 2 diabetes provided excellent fasting and postprandial control with weight loss and no increased risk of hypoglycaemia

被引：0
|
作者：
Bergenstal, R. M. [1 ]
Buse, J. B. [2 ]
Glass, L. C. [3 ]
Heilmann, C. R. [3 ]
Lewis, M. S. [3 ]
Kwan, A. Y. M. [4 ]
Hoogwerf, B. J. [4 ]
Rosenstock, J. [5 ]
机构：
[1] Int Diabet Ctr, Minneapolis, MN USA
[2] UNC Sch Med, Chapel Hill, NC USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Lilly USA LLC, Indianapolis, IN USA
[5] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
73
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [31] Vildagliptin added to once or twice daily insulin regimens improves glycaemic control without increasing risk of hypoglycaemia and weight gain in patients with type 2 diabetes
    Kothny, W.
    Kozlovski, P.
    Foley, J.
    Shao, Q.
    Lukashevich, V.
    [J]. DIABETOLOGIA, 2012, 55 : S354 - S354
  • [32] Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy
    Riddle, M
    Rosenstock, J
    [J]. DIABETOLOGIA, 2002, 45 : A52 - A52
  • [33] Insulin detemir improves glycemic control with reduced risk of hypoglycemia and weight loss in patients previously treated with insulin glargine or NPH insulin
    Meneghini, Luigi
    Koenen, Christoph
    Rojas, Patrick
    Selam, Jean-Louis
    [J]. DIABETES, 2007, 56 : A573 - A573
  • [34] The risk of total hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100
    Kiljanski, J.
    Spaepen, E.
    Harris, C.
    [J]. DIABETOLOGIA, 2018, 61 : S442 - S443
  • [35] Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial
    Wolffenbuttel, B. H. R.
    Nauck, M. A.
    Shaginian, R.
    Malone, J.
    Cleall, S.
    de Vries, D.
    Hoogwerf, B.
    MacConell, L.
    Diamant, M.
    [J]. DIABETOLOGIA, 2013, 56 : S7 - S7
  • [36] Improved glycaemic control and reduced nocturnal hypoglycaemia in patients with Type 2 diabetes with morning administration of insulin glargine compared with NPH insulin
    Fritsche, A
    Schweitzer, MA
    Häring, H
    [J]. DIABETOLOGIA, 2002, 45 : A52 - A52
  • [37] Impact on cardiovascular risk factors of exenatide BID vs insulin lispro TID added to titrated insulin glargine QD in metformin-treated type 2 diabetes mellitus patients: the 4B trial
    Diamant, M.
    Nauck, M. A.
    Shaginian, R.
    Malone, J.
    Cleall, S.
    de Vries, D.
    Hoogwerf, B.
    MacConell, L.
    Wolffenbuttel, B. H. R.
    [J]. DIABETOLOGIA, 2013, 56 : S393 - S394
  • [38] Metabolic improvement associated with temporal pattern of weight loss in exenatide-treated patients with type 2 diabetes
    Kendall, David M.
    Nielsen, Loretta L.
    Han, Jenny
    Fang, Lorna
    Brodows, Robert
    Bhole, Deepak
    [J]. DIABETES, 2008, 57 : A153 - A153
  • [39] Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
    Rosenstock, J.
    Rendell, M. S.
    Gross, J. L.
    Fleck, P. R.
    Wilson, C. A.
    Mekki, Q.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (12): : 1145 - 1152
  • [40] Metabolic Improvement Associated with Temporal Pattern of Weight Loss in Exenatide-Treated Patients With Type 2 Diabetes
    Kendall, David
    Nielsen, Loretta
    Han, Jenny
    Brodows, Robert
    Bhole, Deepak
    [J]. OBESITY, 2008, 16 : S141 - S141
12345